Welcome to the Care Step Pathways

This section provides stand-alone Care Step Pathways (CSPs) that have been customized for the Canadian audience. We wish to thank Massey Nematollahi, RN, MScN,OCN, CON^©, Immuno-Oncology Clinical Nurse Specialist at William Osler Health System in Brampton, Ontario, for thoughtful review of these materials.

List of CSPs

For Immunotherapy (Checkpoint Inhibitors):
Ipilimumab
Nivolumab
Pembrolizumab
Nivolumab/Ipilimumab

• Skin Toxicities – View Online
• Gastrointestinal Toxicities (Diarrhea and Colitis) – View Online
• Thyroiditis – View Online
• Hepatitis – View Online
• Hypophysitis – View Online
• Adrenal Insufficiency, primary – View Online
• Diabetes – View Online
• Pneumonitis – View Online
• Arthralgia/Arthritis – View Online
• Mucositis/Xerostomia – View Online
• Neuropathy – View Online
• Nephritis – View Online

Patient Resources

Action Plans

This section contains the customizable action plans for patients with different tumor types that have been customized for the Canadian audience.

• • Pembrolizumab
    • Bladder (Urothelial) Cancer
    • Hodgkin Lymphoma, Classical
    • Lung Cancer, Non-Small Cell
    • Melanoma
    • MSI-H/dMMR, Other Solid Tumors
  • Nivolumab
    • Head and Neck Squamous Cell Carcinoma
    • Hodgkin Lymphoma, Classical
    • Kidney Cancer (Renal Cell Carcinoma)
    • Liver Cancer (Hepatocellular Carcinoma)
    • Lung Cancer, Non-Small Cell
    • Melanoma
  • Nivolumab/Ipilimumab
    • Kidney Cancer (Renal Cell Carcinoma)
    • Melanoma
  • Ipilimumab
    • Melanoma

Decision-Support Tool for Stage III Melanoma

Newly customized for the Canadian audience, this pamphlet is a document to provide/discuss with patients that helps guide their decision making regarding next steps for stage III melanoma. Reviewed by the Save Your Skin Foundation.